| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Sobetirome (GC-1; QRX-431) is a novel, potent and selective agonist of the thyroid hormone receptor-beta (TRβ) that lowers cholesterol. It binds to TRβ-1 selectively, with an EC50 of 0.16 μM, to produce its effect. In osteoblast-like cells derived from mice and rats, sobetirome suppresses proliferation but promotes differentiation and the expression of TR beta mRNA. The theory that sobetirome would lower cholesterol by activating liver TRbeta without promoting cardiac function by activating heart TRalpha was based on the receptor's selectivity, which allows sobetirome to bind to and activate TRbeta over TRalpha. Based on multiple animal models demonstrating tissue selective thyromimetic properties, sobetirome was developed clinically as a novel agent to lower cholesterol.
| Targets |
TRβ-1 (EC50 = 0.16 μM); TRα-1 (EC50 = 0.58 μM)
|
|---|---|
| ln Vivo |
Sobetirome (GC-1) is a selective agonist for the thyroid hormone receptor β (TRβ) and liver uptake. In euthyroid mice, sobetirome (48 nmol/kg) lowers levels of very low-density lipoprotein (VLDL) triglycerides and high-density lipoprotein (HDL) cholesterol. In hypercholesterolemic mice, sobetirome lowers triglyceride and HDL cholesterol levels. In hypercholesterolemic mice, sobetirome stimulates the synthesis of bile acid and increases the number of HDL receptors in the liver[2]. Treatment with 10× Sobetirome (GC-1) causes only a 21% (1.7 g) increase in fat mass, while treatment with 20× Sobetirome (GC-1) causes a 20% (1.3 g) decrease in fat mass[3].
|
| References |
|
| Molecular Formula |
C20H24O4
|
|---|---|
| Molecular Weight |
328.40216
|
| Exact Mass |
328.17
|
| Elemental Analysis |
C, 73.15; H, 7.37; O, 19.49
|
| CAS # |
211110-63-3
|
| Related CAS # |
211110-63-3
|
| Appearance |
Solid powder
|
| SMILES |
CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)C(C)C)C)OCC(=O)O
|
| InChi Key |
QNAZTOHXCZPOSA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H24O4/c1-12(2)17-9-15(5-6-19(17)21)10-18-13(3)7-16(8-14(18)4)24-11-20(22)23/h5-9,12,21H,10-11H2,1-4H3,(H,22,23)
|
| Chemical Name |
2-[4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-3,5-dimethylphenoxy]acetic acid
|
| Synonyms |
Sobetirome; GC-1; GC 1; GC1; QRX-431; QRX431; QRX 431
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~304.5 mM)
|
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0451 mL | 15.2253 mL | 30.4507 mL | |
| 5 mM | 0.6090 mL | 3.0451 mL | 6.0901 mL | |
| 10 mM | 0.3045 mL | 1.5225 mL | 3.0451 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT01787578 | Withdrawn | Drug: Sobetirome | X-Linked Adrenoleukodystrophy Adrenomyeloneuropathy |
Thomas S. Scanlan | April 2013 | Phase 1 |
| NCT03196765 | Withdrawn | Drug: Sobetirome (NV1205) |
X-Linked Adrenoleukodystrophy | NeuroVia, Inc. | August 2018 | Phase 1 Phase 2 |
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
